Not medical advice. This site is general information only. In an emergency call your local emergency number. For advice about your own health, speak to a doctor, pharmacist or other qualified health professional.
Alirocumab
About Alirocumab
A PCSK9 inhibitor that dramatically lowers LDL cholesterol. Alirocumab or Praluent treats patients with familial hypercholesterolemia or those who cannot reach cholesterol targets on statins. PCSK9 inhibitors are monoclonal antibodies given by subcutaneous injection. They can lower LDL by 50 to 60 percent on top of statins. The ODYSSEY OUTCOMES trial showed reduced cardiovascular events. PCSK9 inhibitors are expensive, limiting access. Insurance often requires prior authorization. The discovery of PCSK9 as a drug target came from studying families with unusually low cholesterol and low heart disease rates.
Related Medications
Trastuzumab
A monoclonal antibody targeting HER2 positive breast cancer. Trastuzumab or Herceptin treats the roughly 15 to...
Rituximab
The first monoclonal antibody approved for cancer treatment. Rituximab or Rituxan targets CD20, a protein on B...
Bevacizumab
A monoclonal antibody that cuts off tumor blood supply. Bevacizumab or Avastin targets VEGF, a protein that st...
Evolocumab
A PCSK9 inhibitor that is the best selling drug in its class. Evolocumab or Repatha treats familial hyperchole...